Amy Drescher-Crumpley, CNM
Psychiatric/Mental Health · St Charles, ILNPI 1801907589
Payments from drug & device makers
Across 28 payments — averaging $21.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$151
- Corium, LLC$103
- Otsuka America Pharmaceutical, Inc.$94
- Johnson & Johnson$71
- Lundbeck LLC$58
- Tris Pharma Inc$49
- plus $89 from 4 others
What the payments were for
- Food & beverage$614100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $151 |
| Corium, LLC | 5 | $103 |
| Otsuka America Pharmaceutical, Inc. | 4 | $94 |
| Johnson & Johnson | 3 | $71 |
| Lundbeck LLC | 3 | $58 |
| Tris Pharma Inc | 2 | $49 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| AbbVie | 1 | $20 |
| Alkermes, Inc. | 1 | $18 |
How this compares
$614 in reported general payments places this provider in the 55th percentile of 922 psychiatric/mental health providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 61 | $2,524 |
| Duloxetine Hcl | 56 | $1,284 |
| Bupropion XlBupropion Hcl | 36 | $1,192 |
| Fluoxetine Hcl | 32 | $745 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 15 | $655 |
| Mirtazapine | 20 | $468 |
| Bupropion Hcl SrBupropion Hcl | 16 | $436 |
| Gabapentin | 27 | $431 |
| Olanzapine | 18 | $418 |
| Trazodone Hcl | 31 | $353 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 25 | $338 |
| Methylphenidate ErMethylphenidate Hcl | 11 | $330 |
| Sertraline Hcl | 34 | $318 |
| Clonazepam | 53 | $306 |
| Escitalopram Oxalate | 22 | $280 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in St Charles
- Erin PetrusicChicago$517K
- Maurice BrownleeChicago$162K
- Melissa VitaleChicago$151K
- Alan AmbergChicago$119K
- Jaime MendozaMaryville$111K
- Jennifer TheryMaryville$83K
- Carole Weddington HuntGranite City$67K
- Jessica WhelanBloomington$55K
- Lynn LochnerKankakee$41K
- Julie CarbrayChicago$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.